Vor Biopharma (Vor Biopharma) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Vor Biopharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Vor Biopharma's Free Cash Flow for the three months ended in Dec. 2023 was $-24.14 Mil. Vor Biopharma's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Vor Biopharma's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Vor Biopharma's current FCF Yield % is -87.92%.

The historical rank and industry rank for Vor Biopharma's FCF Margin % or its related term are showing as below:

VOR's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -148.935
* Ranked among companies with meaningful FCF Margin % only.

Vor Biopharma FCF Margin % Historical Data

The historical data trend for Vor Biopharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vor Biopharma FCF Margin % Chart

Vor Biopharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

Vor Biopharma Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial														-	-	-	-	-

Competitive Comparison of Vor Biopharma's FCF Margin %

For the Biotechnology subindustry, Vor Biopharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vor Biopharma's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vor Biopharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Vor Biopharma's FCF Margin % falls into.

Vor Biopharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Vor Biopharma's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-101.361	/	0
	=	%

Vor Biopharma's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-24.137	/	0
	=	%

Vor Biopharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of Vor Biopharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Vor Biopharma (Vor Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vor Biopharma Inc (NAS:VOR) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Cambridgepark Drive, Suite 101, Cambridge, MA, USA, 02140

Website

https://www.vorbio.com

Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.

Executives

Eyal C. Attar	officer: Chief Medical Officer	535 BOYLSTON STREET, BOSTON MA 02116
5am Ventures Vi, L.p.	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar	director, 10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Nathan D. Jorgensen	officer: Chief Financial Officer	C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Christopher Slapak	officer: Chief Medical Officer	C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Sadik Kassim	officer: Chief Technology Officer	C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Tirtha Chakraborty	officer: Chief Scientific Officer	C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Robert Ang	director, officer: President and CEO	C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
5am Partners Vi, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
David Charles Lubner	director	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Puretech Health Llc	10 percent owner	501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Daniella Beckman	director	C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
5am Opportunities I (gp), Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I, L.p.	10 percent owner	501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107